How has been the historical performance of Glaxosmi. Pharma?

Answer:The historical performance of Glaxosmi. Pharma shows a steady growth in net sales and profitability over the years, with significant fluctuations in certain metrics.

Breakdown:
Glaxosmi. Pharma's net sales have increased from 3,128.12 Cr in Mar'19 to 3,749.21 Cr in Mar'25, reflecting a consistent upward trend. The total operating income followed a similar trajectory, rising from 3,128.12 Cr in Mar'19 to 3,749.21 Cr in Mar'25. The company's operating profit (PBDIT) has also shown improvement, climbing from 703.11 Cr in Mar'19 to 1,323.29 Cr in Mar'25, with an operating profit margin that increased from 19.21% to 31.4% over the same period. Profit before tax reached 1,259.88 Cr in Mar'25, up from 682.66 Cr in Mar'19, while profit after tax saw a notable rise to 927.58 Cr in Mar'25 from 445.39 Cr in Mar'19. The earnings per share (EPS) surged from 26.29 in Mar'19 to 54.75 in Mar'25, indicating enhanced shareholder value. On the balance sheet, total assets increased from 3,025.05 Cr in Mar'20 to 3,967.20 Cr in Mar'25, while total liabilities also rose from 3,025.05 Cr to 3,967.20 Cr during the same period. Cash flow from operating activities improved significantly, reaching 1,289.00 Cr in Mar'25 compared to 490.00 Cr in Mar'20, contributing to a closing cash balance of 538.00 Cr in Mar'25, up from 104.00 Cr in Mar'20. Overall, Glaxosmi. Pharma has demonstrated robust growth in sales, profits, and cash flow, despite some fluctuations in expenses and liabilities.